Strimpakos Alexios Internist Oncologist

Doctoral thesis

• Medical School, University of Athens in 2015

‘‘Alteration of apoptotic and programmed cell death markers after induction of chemotherapy in solid tumors’’

Fellowship in Societies, Membership in Journal Editorial Committees

• European Society of Medical Oncology (ESMO) since 2008

• American Society of Clinical Oncology (ASCO) since 2009

• European Society Digestive Oncology (ESDO) since 2015

• Royal College of Physicians (MRCP) since 2005

• General Medical Council (GMC-6055877) since 2002

• Athens Medical Association (No 057597) since 1999

Editorial Boards

• Clinical Trials and Practice

Has also served as Peer Reviewer in the journals:

• Cancer Chemother. Pharmacol. Since Feb 2009

• Pharmacogenomics J., since Jun 2009

• Annals Of Oncology, since Sept 2010

• Cutaneous and Ocular Toxicology. Since March 2012

• Therapeutic Advances in Medical Oncology, since March 2012

• JOP. Journal of the Pancreas, since October 2012

Work Experience

• From January 2019 Medical Oncologist at Hygeia Group (Hygeia & Mitera Hospitals)

• November 2016- December 2018: Consultant Medical Oncologist & Director of Dept of Medical Oncology at Athens Medical Center Hospital

• July 2015- October 2016: Consultant Medical Oncologist & Director of 4^th Dept of Medical Oncology at Euroclinic Athens Hospital

• May 2013-June 2015: Senior Clinical Research Fellow in Medical School of Athens and Locum Consultant Medical Oncologist, at the Oncology Unit, 2^rd Dept of Medicine, University of Athens, ‘Attikon” General Hospital.

• May 2013-June 2015: Senior Clinical Research Fellow in Medical School of Athens and Locum Consultant Medical Oncologist, at the Oncology Unit, 3^rd Dept of Medicine, University of Athens, Sotiria General Hospital. Completed the research project – Thesis ‘apoptotic markers in solid tumours following chemotherapy’.

• Feb 2006- April 2009: Training in Med. Oncology at The Royal Marsden Hospital, London UK.

• Dec 2002– Feb 2006:  SHO in Medicine, United K

• Jul 2001 – Oct 2002:  Resident in the Emergency Dept at the Kyparissia’s Hospital, Greece.

• Nov 1999 – May 2001:  Military in the Greek army (National Service).

Education Experience

• 2009-2015  Regular teaching and tutoring of Undergraduate Medical Students of the University of Athens at Sotiria General Hospital and “Attikon” University Hospital

• 2009-2015 Teaching and tutoring of Internal Medicine Residents at Sotiria General Hospital and “Attikon” University Hospital

• 2013-2015 Teaching and tutoring of Medical Oncology Residents at “Attikon” University Hospital

• 2010-2013 Teaching in Postgraduate Students undertaking Master of Science projects in the University of Athens

Clinical & Research Interest

Clinical Interest:

• All types of Solid tumours with special focus to Gastrointestinal Cancers, Aerodigestive cancers, Lung Cancer, Breast Cancer, Urological cancers and Palliative Care

Research Interest: 

• Gastrointestinal Cancers, Lung Cancer, Personalized and Translational Medicine

Honors & Awards

• Educational Grant from Hellenic society of Medical Oncology for the research project «Alteration of apoptotic and programmed cell death markers after induction of chemotherapy in solid tumors”. (2010)

Recent Publications

1. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. Anticancer Res. 2016 Apr;36(4):1581-90.

2. Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology. 2015;89(1):53-9.

3. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol. 2013 Nov;72(5):935-52.

4. The clinical significance of cytology versus histology-based diagnosis in small cell lung cancer: a retrospective study. Lung Cancer. 2014

5. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013 Dec;12(4):267-274

6. Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology. 2015 Feb 28

7. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study.  Anticancer Res. 2016 Apr;36(4):1581-90

8. «The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy». Ann Oncol. 2009 Oct 27 

9. “ Pharmacogenetics and biomarkers in Colorectal cancer”. The Pharmacogenomics J. 2009 Jun;9(3):147-60

10. Comprehensive review: Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials. Antioxid Redox Signal.2008, Mar;10(3): 511-45 (>540 citations)

List of publications (>870 Citations)

https://www.ncbi.nlm.nih.gov/pubmed/?term=strimpakos+a